Maravai LifeSciences
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and...
Latest News
10 days ago · seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call TranscriptMaravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Brendan Smith - TD Cowen, Research Division Justin Bowers - Deutsche Bank AG, Research Division Sean Gardner - UBS Investment Bank, Research Division Jacob Krahenbuhl - William Blair & Company L.L.C., Research Division Matthew Parisi - KeyBanc Capital Markets Inc., Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Hello, and welcome, everyone, joining today's Maravai LifeSciences Q3 2026 Results Earnings Call.
12 days ago · marketbeat.com
What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings CallMaravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business.
12 days ago · zacks.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue EstimatesMaravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
1 month ago · businesswire.com
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav.
3 months ago · seekingalpha.com
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables FlywheelMaravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.
3 months ago · seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call TranscriptMaravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
3 months ago · zacks.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue EstimatesMaravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
3 months ago · businesswire.com
Maravai LifeSciences Reports Second Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.
4 months ago · businesswire.com
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.
6 months ago · businesswire.com
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MRVI